After receiving a simple COVID-19 treatment, a six-month-old baby boy's eye colour reportedly changed from dark brown to bright blue. The infant from Thailand was diagnosed with COVID-19 after he showed symptoms of fever and cough for a day, as mentioned in a case published in the medical journal Frontier in Pediatrics.

Infant's eye colour changes from dark brown to bright blue after COVID-19 treatment: Report

Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world`s third worst-hit nation show no sign of abating.

Cipla gets India approval to sell COVID-19 drug Favipiravir

Favipiravir and anti-viral medication developed in Japan is currently the subject of 18 trials around the world as a potential treatment for COVID-19. Watch report.

Drug to cure mild to moderate symptoms of COVID-19: 'Favipiravir' or 'Fabiflu'

Days after Glenmark Pharmaceuticals launched its anti-viral drug to treat coronavirus patients, the company's shares surged 40 per cent to Rs 572.7 on Monday in the intra-day trade on the BSE.

Glenmark's shares rise up to 40% following launch of potential coronavirus drug

The Drug Controller General of India (DCGI) has granted permission to use the anti-viral drug favipiravir for COVID-19 patients. However, the drugis only for "restricted emergency use" in mild to moderate cases of COVID-19, according to official sources.

COVID 19: Anti-viral drug Favipiravir gets DCGI nod for 'restricted emergency use'

Russia, which is the third-worst affected country by coronavirus, is planning to start clinical trials within two weeks on a vaccine to combat the coronavirus, the health minister reported on Saturday.

COVID 19: Russia to start vaccine trials within two weeks

favipiravir

Favipiravir, News on Favipiravir, stories on Favipiravir, articles on Favipiravir, Favipiravir stories at Wion, Favipiravir news, Favipiravir latest news